Quanterix Corporation
quanterix.comWhat Do They Do?
Sells protein-detection and tissue-analysis systems, assay consumables, and research and clinical testing services to research labs and universities, drug and biotech companies, and contract research organizations.
How Do They Make Money?
The largest stream is instrument, assay-kit and other consumable sales; instruments are sold at shipment or delivery, or after required installation. Consumables bring repeat purchases, while the company also earns from research and clinical testing services and license royalties tied to sales or use.
10-K for FY2025, filed Mar 2, 2026Recurring revenue is derived through the sale of consumables used to run assays on our instruments and from our growing menu of Simoa…View ↗
Product RevenueView ↗
Product revenues for direct instrument sales to customers are recognized when the related performance obligation(s) are satisfied (i.e.…View ↗
We sell our proprietary instruments and related consumables worldwide to research laboratories, contract research organizations ("CROs")…View ↗
The Company determines the transaction price of its contracts based on the amount of consideration it expects to be entitled to, which is…View ↗
$138.9M
-
10-K for FY2025, filed Mar 2, 2026
$138.9M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue
Mix
10-K for FY2025, filed Mar 2, 2026 |
67%
FY2022: 66%
|
Product revenue, FY2025
$92.9M Sources
|
Mix |
|
Service and Other Revenue
|
32%
FY2022: 33%
|
Service and Other Revenue, FY2025
$44.2M Sources
|
|
|
Collaboration and license revenue
Licensed
|
1.1%
FY2022: 0.6%
|
Collaboration and license revenue, FY2025
$1.5M Sources
|
Licensed |
Who Are Their Customers?
Research labs, contract research organizations, academic and government institutions, and drug and biotech companies buy through direct sales in North America and Europe, and through the company’s sales teams or distributors elsewhere.
10-K for FY2025, filed Mar 2, 2026We have an extensive base of worldwide customers including research laboratories, contract research organizations ("CROs"), academic…View ↗
We distribute our instruments and consumables via direct field sales and support organizations located in North America and Europe and…View ↗
The Company’s customers primarily consist of entities engaged in the life sciences research that pursue the discovery and development of…View ↗
Do Revenues Turn Into Profits?
No. It lost $107.2M in FY2025.
10-K for FY2025, filed Mar 2, 2026
−$125.5MView ↗
10-K for FY2025, filed Mar 2, 2026
−$107.2MView ↗
10-K for FY2025, filed Mar 2, 2026
−$79.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$48.9MView ↗
- ▲ +63% (Loss)
- vs −$30M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 10, 2026
Open tableView ↗
-
Aug 10, 2026
Cuts 2026 revenue outlook and delays cash-flow break-even
Revenue outlook is $142-148 million versus $169-174 million previously; cash-flow break-even is now expected in 2027.
Sources
8-K, filed Aug 10, 2026
Quanterix currently expects revenues of $142-148 million, which assumes no underlying improvement in the academic or pharmaceutical end…View ↗
-
Jun 9, 2026
Appoints Jason Faessler chief financial officer
Jason Faessler was appointed CFO and Treasurer, with employment expected to begin June 22, 2026.
Sources
8-K, filed Jun 9, 2026
The Board of Directors of Quanterix Corporation (the “Company”) has appointed Jason Faessler as the Chief Financial Officer and Treasurer…View ↗
-
May 12, 2026
Announces chief financial officer departure
Vandana Sriram was set to leave as CFO and Treasurer effective June 15, 2026.
Sources
8-K, filed May 12, 2026
Vandana Sriram will be leaving Quanterix Corporation (the “Company”) and will no longer serve as the Chief Financial Officer and Treasurer…View ↗
Adds spatial biology
The older report centered on Simoa protein detection in blood and other fluids; the latest also describes spatial-biology platforms that analyze biomarkers in intact tissue.
10-K for FY2022, filed Mar 6, 2023We are a life sciences company that has developed next-generation, ultra-sensitive digital immunoassay platforms that advance life sciences…View ↗
Broadens clinical testing
The older report described LDTs as a recent offering; the latest also describes a multi-marker Alzheimer’s LDT and clinical laboratory testing.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 2, 2026We also provide contract research services for customers through our CLIA-certified Accelerator Laboratory. The Accelerator Laboratory…View ↗
Who Do They Compete With?
Competes with Bio-Techne, MesoScale Discovery, SEER, Bio-Rad Laboratories, Alamar, Spear Bio, 10x Genomics, Vizgen, Bruker, Miltenyi Biotec, Standard BioTools, LabCorp, Covance, Q2 Solutions, Rules Based Medicine, Monogram Biosciences, Frontage, Thermo Fisher Scientific, Roche, and Fujirebio
10-K for FY2025, filed Mar 2, 2026We compete with both established and development-stage life science companies that design, manufacture, and market instruments for…View ↗
Loading...
